Ambroxol, a repurposed cough suppressant, shows potential as a disease-modifying therapy for Parkinson's by enhancing lysosomal function and clearing α-synuclein aggregates, with the GREAT trial currently evaluating its efficacy.
Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.